Latest Articles
-
2x Returns Possible For Pfizer Stock?
Pfizer stock (NYSE: PFE) is trading at about $30 per share, not far from the lows seen in recent years. Could the stock rise by over 2x in value over the next few years? Does this sound a bit ridiculous? Consider this – Pfizer stock was trading...
-
Is Pfizer Stock A Better Pick Over AbbVie?
Given its better valuation, we believe that Pfizer stock (NYSE: PFE) is currently a better pick than its industry peer – AbbVie stock (NYSE:ABBV). PFE stock trades at a much lower multiple of 11x forward, versus 20x for ABBV, and we think thi...
-
Was Q2 The Turning Point For Pfizer Stock?
With Pfizer’s sales rising in Q2, despite falling sales of Covid-19 products, we think that it may well be the turning point for Pfizer stock (NYSE:PFE). It has seen a decline of 15% from levels of $35 in early January 2021 to around $30 ...
-
Will Pfizer Stock Post A Downbeat Q2?
Pfizer (NYSE: PFE) is scheduled to report its Q2 2024 results on Tuesday, July 30. We expect the company to post revenue of $12.95 billion and earnings of $0.44 on a per share and adjusted basis, lower than the consensus estimates. The company is...
-
Pfizer vs. Eli Lilly Stock – Which Is A Better Pick?
We believe that Eli Lilly stock (NYSE: LLY) is currently a better pick than its industry peer – Pfizer stock (NYSE:PFE), given its better prospects. PFE stock trades at a much lower multiple of 2.8x revenues, versus 23.5x for LLY, and we thin...
-
Will Pfizer Stock Rebound To Its 2021 Highs Of $60?
Pfizer stock (NYSE: PFE) currently trades at $28 per share, 55% below its peak level of $61 seen in December 2021. In contrast, Merck stock (NYSE:MRK) is up 36% over this period. PFE stock was trading at $52 in early June 2022, just before the ...
-
Is Pfizer Stock Fully Valued At $28?
Pfizer (NYSE: PFE) reported its Q1 results last week, with revenues and earnings beating the street estimates. The company reported revenue of $14.9 billion and an adjusted profit of $0.82 per share, compared to the consensus estimates of $14.0...
-
What Factors Will Drive Pfizer’s Q1 Performance?
Pfizer (NYSE: PFE) is scheduled to report its Q1 2024 results on Wednesday, May 1. We expect the company to post revenue of $13.8 billion and earnings of $0.50 on a per share and adjusted basis. The company is likely to see a continued decline in...
-
After A 30% Fall In A Year Is Pfizer Stock A Better Pick Over Merck?
Given its attractive valuation, we believe Pfizer stock (NYSE: PFE) is a better pick than its peer — Merck stock (NYSE: MRK). MRK trades at a higher valuation multiple of 5.6x revenues vs. 2.7x for PFE, due to its superior revenue growth ov...
-
Should You Pick Pfizer Stock At $30 After A 30% Fall In A Year?
Pfizer (NYSE: PFE) reported its Q4 results last month, with revenues missing but earnings beating the street estimates. The company reported revenue of $14.2 billion and an adjusted profit of $0.10 per share compared to the consensus estimates ...
-
Should You Pick Pfizer Stock At $30?
Pfizer (NYSE: PFE) reported its Q3 results earlier this week, with revenues missing but earnings beating the street estimates, and we believe that PFE stock has ample room for growth, as discussed below. The company reported revenue of $13.2 bi...
-
Down 25% In A Year Will Pfizer Stock Rebound To Its Pre-Inflation Shock Level?
Pfizer stock (NYSE: PFE) currently trades at $37 per share, aligning with the level seen in March 2021, and it can see higher levels over time. PFE stock was trading at around $52 in early June 2022, just before the Fed started increasing rates...
-
Will Pfizer Stock See Higher Levels Post Q1 Earnings?
Pfizer (NYSE: PFE) is scheduled to report its Q1 2023 results on Tuesday, May 2, and we expect it to see higher levels, with its revenue and earnings expected to exceed the consensus estimates. Its Covid-19 vaccine and the antiviral pill will see...
-
Is Pfizer Stock Undervalued At $40?
Pfizer stock (NYSE: PFE) has seen a fall of 21% this year, compared with 2% returns for the broader S&P500 index. Pfizer stock has been weighed down due to an anticipated decline of over 30% in its 2023 sales, primarily due to lower sales o...
-
This Logistics Company Appears To Be A Better Pick Over Pfizer Stock
We believe that FedEx stock (NYSE: FDX) is a better pick than the pharmaceutical giant Pfizer stock (NYSE: PFE), given its better prospects. Although these companies are from different sectors, we compare them because they have a similar re...
